3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Esophageal Squamous Cell Carcinoma
5
Neoplasm Metastasis
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Recurrence
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Sarcoma
1
Neuroendocrine Tumors
1
Nasopharyngeal Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Locally Advanced or Metastatic Urothelial Bladder Cancer
1
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
pembrolizumab
1
ioflupane
1
idelalisib
1
aflibercept
1
Water
1
Vertical Dimension
1
Methylene Blue
1
Mammography
1
Drug Delivery Systems
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Disease
×
tislelizumab
×
Clear all
No trials found.